TY - JOUR
T1 - Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus
AU - Rodríguez, Rosa Polo
AU - Puerto, María José Galindo
AU - Dueñas, Carlos
AU - Candela, Carmen Gómez
AU - Estrada, Vicente
AU - Villar, Noemí G.P.
AU - Locutura, Jaime
AU - Mariño, Ana
AU - Pascua, Javier
AU - Palacios, Rosario
AU - Von Wichmman, Miguel Ángel
AU - Álvarez, Julia
AU - Asensi, Victor
AU - Aldeguer, José Lopez
AU - Lozano, Fernando
AU - Negredo, Eugenia
AU - Ortega, Enrique
AU - Pedrol, Enric
AU - Gutiérrez, Félix
AU - Sanz, Jesús Sanz
AU - Chamorro, Esteban Martínez
PY - 2015/1/1
Y1 - 2015/1/1
N2 - © 2014 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved. Objective: This consensus document is an update of metabolic disorders and cardiovascular risk (CVR) guidelines for HIV-infected patients. Methods: This document has been approved by an expert panel of GEAM, SPNS and GESIDA after reviewing the results of efficacy and safety of clinical trials, cohort and pharmacokinetic studies published in biomedical journals (PubMed and Embase) or presented in medical scientific meetings. Recommendation strength and the evidence in which they are supported are based on the GRADE system. Results: A healthy lifestyle is recommended, no smoking and at least 30 min of aerobic exercise daily. In diabetic patients the same treatment as non-HIV infected patients is recommended. HIV patients with dyslipidemia should be considered as high CVR, thus its therapeutic objective is an LDL less than 100 mg/dL. The antihypertensive of ACE inhibitors and ARA II families are better tolerated and have a lower risk of interactions. In HIV-patients with diabetes or metabolic syndrome and elevated transaminases with no defined etiology, the recommended is to rule out a hepatic steatosis Recommendations for action in hormone alterations are also updated. Conclusions: These new guidelines update previous recommendations regarding all those metabolic disorders involved in CVR. Hormone changes and their management and the impact of metabolic disorders onthe liver are also included.
AB - © 2014 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved. Objective: This consensus document is an update of metabolic disorders and cardiovascular risk (CVR) guidelines for HIV-infected patients. Methods: This document has been approved by an expert panel of GEAM, SPNS and GESIDA after reviewing the results of efficacy and safety of clinical trials, cohort and pharmacokinetic studies published in biomedical journals (PubMed and Embase) or presented in medical scientific meetings. Recommendation strength and the evidence in which they are supported are based on the GRADE system. Results: A healthy lifestyle is recommended, no smoking and at least 30 min of aerobic exercise daily. In diabetic patients the same treatment as non-HIV infected patients is recommended. HIV patients with dyslipidemia should be considered as high CVR, thus its therapeutic objective is an LDL less than 100 mg/dL. The antihypertensive of ACE inhibitors and ARA II families are better tolerated and have a lower risk of interactions. In HIV-patients with diabetes or metabolic syndrome and elevated transaminases with no defined etiology, the recommended is to rule out a hepatic steatosis Recommendations for action in hormone alterations are also updated. Conclusions: These new guidelines update previous recommendations regarding all those metabolic disorders involved in CVR. Hormone changes and their management and the impact of metabolic disorders onthe liver are also included.
KW - Cardiovascular risk
KW - Human immunodeficiency virus infection
KW - Metabolic disorders
U2 - 10.1016/j.eimc.2014.06.006
DO - 10.1016/j.eimc.2014.06.006
M3 - Article
SN - 0213-005X
VL - 33
SP - 40.e1-40.e16
JO - Enfermedades Infecciosas y Microbiologia Clinica
JF - Enfermedades Infecciosas y Microbiologia Clinica
IS - 1
ER -
